GICS

No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab

Liposomal irinotecan regimen boosts outcomes, although expert expressed concern about toxicity

Longest overall survival reported to date with the addition of zolbetuximab to chemotherapy

Nearly identical 3-year survival, questioning the need for radiotherapy before surgery

Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer

The KRAS G12C inhibitor showed a disease control rate of 100% in small study

Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade

No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab

Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib

Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer

Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression

Chemotherapy alone judged efficacious but not chemoradiation

Test for ctDNA outperformed existing biomarker, may help guide therapy

PFS, OS improved with fibroblast growth factor receptor inhibitor in non-HER2 disease